Cipla gets USFDA nod for osteoarthritis of joint pain relief gel

Cipla gets USFDA nod for osteoarthritis of joint pain relief gel Citing IQVIA data, the company said Voltaren Gel and its generic equivalents had US sales of approximately $353 million for the 12 month period ending June 2018.

No comments:

Post a Comment